ClinicalTrials.gg
CompletedNCT05995665Updated Jul 13, 2026

Assistive Soft Robotic Glove (EsoGLOVE) Intervention for Stroke Patients

An interventional study of EsoGLOVE and Graded Repetitive Arm Supplementary Program (GRASP) in Stroke, sponsored by Alexandra Hospital. Completed at 2 sites in Singapore. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Alexandra Hospital · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Stroke with a site in Singapore — 16 open to participants now, 21 under way, 1 of them phase 3. Stroke · Singapore.

Enrollment
38th of 86
61 · median 51
Started
2023
with 6 others
No phase
58 of 104
13 open now
Registered
78th of 104
by date

Among the 104 studies in Stroke with a site in Singapore, this one is the 38th largest by enrollment of the 86 interventional ones that give a count, is one of 7 that started in 2023, is one of 58 with no phase, and was the 78th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

16 of the 104 studies in Stroke with a site in Singapore are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Stroke with a site in Singapore, or all of them as a file.
02

Study summary

This proposed research aims to assess the efficacy and feasibility of the EsoGLOVE in the inpatient rehabilitation setting. 1. Understanding the ability of the EsoGLOVE in providing exercise and assisting stroke patients with completing hand functional tasks, eventually improves patients' motor function and neural recovery.2. To generate evidence on this innovative device and further deploy it in clinical practice. A Health Technology Assessment (HTA) will be generated from this study to evaluate the cost-effectiveness of the intervention.

Read the detailed description

This project proposes a study of 130 subjects in inpatient settings who have sustained their first-ever stroke prior to clinical trial enrolment. Participants are randomly assigned to 2 groups (EsoGLOVE group and GRASP group). The randomization method: A block randomization with a randomly varying block size. The study will last 12 weeks (3 weeks of intervention during hospitalization + 12th-week outpatient follow-up post-discharge). The subjects will use the study device about 15 times and be followed up for 3 weeks during hospitalization.

The subjects will need to visit the doctor's office 1 time (outpatient follow-up post-discharge) in the course of the study.During the hospitalization, the stroke patients (subjects) will receive intensive stroke rehabilitation as per normal, which will be daily physiotherapy and occupational therapy as a part of standard care as per stroke rehabilitation. On top of the standard care (daily Inpatient OT Rehabilitation), the EsoGLOVE subjects will receive EsoGLOVE training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day. While the GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.In the case of early discharge or withdrawal for any reason before the 3-week intervention is completed, the subjects will no longer participate in this study and no study-related activities will be performed on the subjects. The subjects' right to receive standard care will remain the same as per hospital guidelines and will not be affected. This is applicable to both groups. With minimal compliance rate (10 sessions) for continuing the study, regardless of the subjects' discharge before 3 weeks, otherwise (less than or equal to 9 sessions) subjects will be withdrawn at the day of discharge or withdrawal. The 12th-week outpatient follow-up post-discharge at the clinic will coincide with the subject's standard care follow-up visit.The Health Technology Assessment (HTA) is conducted by the study team using explicit analytical frameworks, clinical outcomes, epidemiological data amp; statistics, health economic information, and study methodology. The assessment includes building evidence on the qualities and costs of health interventions (cost-effectiveness), identifying the direct amp; indirect medical costs in the current healthcare system, capturing the clinical outcomes of interventions, synthesizing health research findings of the effectiveness of different health interventions, evaluating the economic implications and analyzing the cost-effectiveness of the intervention.It is unlikely this study might unintentionally come to know of new information (Incidental Finding) about the health condition from the assessment (Fugl-Meyer Assessment - Upper Extremity) of the study.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 21-90 years regardless of lesion size, race
  2. Stroke type: ischemic or haemorrhagic
  3. Medically stable conditions
  4. Fugl-Meyer Assessment (FMA) of upper extremity impairment from 8-47 out of 66, or FMA of upper extremity impairment from 48-56 out of 66 if hand and wrist subscale is not full score and may still potentially benefit from study programme.
  5. Able to give own consent, comprehend and follow commands
  6. Able to sit upright and maintain sitting balance for at least 45 minutes
  7. Able to stay alert and focus on the tasks at least 45 minutes and more.
  8. Unilateral upper limb impairment

Exclusion criteria

Exclusion Criteria:

  1. Recurrent stroke
  2. Unstable medical conditions (e.g. heart attack, unstable blood pressure, infection, and etc.) or anticipated of \<1 year.
  3. Significant cognitive and communicative impairment (e.g. severe receptive aphasia, inattention, learning difficulty, and etc).
  4. History of severe depression or active psychiatric disorder.
  5. Severe spasticity (Modified Ashworth scale >3) of the affected distal muscles, joint contractures or deformity, poor skin conditions (e.g. irritated skin, open wounds), amputation of fingers, and allergic condition (e.g. patients with allergies to adhesive gel).
  6. Poor trunk control or postural hypotension.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    EsoGLOVE

    The EsoGLOVEGroup subjects will receive EsoGLOVE training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day

    Device: EsoGLOVE

  • Active comparator
    Graded Repetitive Arm Supplementary Program (GRASP) Group

    The GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day

    Other: Graded Repetitive Arm Supplementary Program (GRASP)

Interventions

  • DeviceEsoGLOVE

    The dose is referred to the stay of inpatient setting. The stroke patients will be transferred to community hospital when medically stable. The average of stay in community hospital is 3 weeks. The stroke patients will receive intensive stroke rehabilitation during the stay, which will be daily physiotherapy and occupational therapy. The subjects will receive EsoGLOVE training on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day, up to 15 sessions. This is similar to the dose in a similar trial (DSRB 2017/00312, Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture).

  • OtherGraded Repetitive Arm Supplementary Program (GRASP)

    Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.

06

What researchers measure

Primary outcomes

  1. Fugl-Meyer Assessment for the Upper Extremity

    upper limb impairment scale ranged from 0-66 with higher score indicating better outcome

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

Secondary outcomes

  1. Stroke Impact Scale-16

    consists of 16 items from the 4 physical domains (strength, hand function, mobility, and ADL/IADL) ranged from 16 to 80 with higher score indicating better outcome

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

  2. Stroke Upper Limb Capacity Scale

    Activities limitation of upper limb ranged 0 to10 with higher score indicating better outcome

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

  3. Duruoz Hand Index

    self-reported upper limb function ranged 0 to 90 with higher score indicating worse outcome

    Time frame: Baseline, immediately post-intervention and 3 months post-intervention

07

Study locations

2 sites
  • Alexandra Hospital
    Singapore, Singapore
  • Jurong Community Hospital
    Singapore, Singapore
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Aug 2025, 25 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 25 months is close to that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 16, 2023
StartActual
Jul 11, 2023
Primary completionActual
Aug 31, 2025
CompletionActual
Aug 31, 2025
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05995665
Lead sponsor
Alexandra Hospital
Collaborators
Jurong Community Hospital, Singapore, Roceso Technologies
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Jul 11, 2023
Primary completion
Aug 31, 2025
Completion
Aug 31, 2025
Last update
Jul 13, 2026

Study contacts

Pui Kit Tam, MBBS
principal investigator · Alexandra Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion